All News
TitAIN Study: Secukinumab Efficacy in Giant Cell Arteritis
A phase 2 trial has demonstrated the efficacy of secukinumab, an anti-interleukin-17A monoclonal antibody, in patients with active giant cell arteritis (GCA).
Read Article
What is Colchicine Worth? (6.23.2023)
Dr. Jack Cush reviews the news and reports from the past week on RheumNow.com. This week a new colchicine FDA approval, rising rate of IgG4 related disease and what's the safest biologic?
Read Article
Why Patients Don't Take Medicines
d
CDC
About 60% of adults aged 18 and over reported taking at least one prescription medication in 2021, with 36% reporting taking three or more. Out-of-pocket costs on retail drugs rose 4.8% to $63 billion in 2021.
Read Article
FDA Approves Colchicine for CV Prevention
The FDA has approved colchicine (Lodoco) for cardiovascular prevention in adults with established atherosclerotic disease or multiple risk factors, making it the first anti-inflammatory medicine with such an indication.
Read Article
Ultrasonography May Improve OA Pain Prediction
Dr. Bella Mehta reports on POS0107 from EULAR 2023 in Milan, Italy.
https://t.co/ZHBdWPWTys https://t.co/JLIScNVZGB
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR 2023 Lupus Highlights
https://t.co/CGybJRjDDK https://t.co/2kkB1hX2J5
Links:
Dr. John Cush RheumNow ( View Tweet)
Are bDMARDs, tsDMARDs and biosimilar DMARDs cost effective?
The use of methotrextate with either bDMARDs, tsDMARDs or bsDMARDs was not shown to be cost effective, even though reduced disease activity and improved patient quality of life.
Read more--https://t.co/4nBp0ML8Kl https://t.co/5YXCotHlYK
Links:
Dr. John Cush RheumNow ( View Tweet)
Cancer Risk From RA, Not the Drugs
A large US claims analysis shows RA patients were nearly 2 times more likely (than those without RA) to develop lymphoma or lung cancer and that commonly used RA treatments were also unlikely to increase cancer risk.
https://t.co/6yrc0TsT53 https://t.co/WRQzeFoR1Z
Links:
Dr. John Cush RheumNow ( View Tweet)
An RCT of 1136 newly COVID test positive pts compared long term outcomes if immediately given METFORMIN or Placebo. Cumulative incidence of long COVID at day 300 was 6.3% w/ metformin vs 10.4% w/ placebo (HR 0.59; HR 037 if given w/in 3d) https://t.co/aCTX7xFewW https://t.co/xbBeED9K7U
Links:
Dr. John Cush RheumNow ( View Tweet)
Australian CRISTAL RCT 23 458 OA adults undergoing hip or knee replacements & given ASA 100 mg/d or SC enoxaparin 40 mg qd for 35 days (THR) or 14 days(TKR) for VTE prophylaxis = no difference betw groups: 90D mortality was 1.67% vs 1.53% https://t.co/wBLtlyCcsF https://t.co/WFkZ2KNHFF
Links:
Dr. John Cush RheumNow ( View Tweet)
Abatacept Safety Outcomes Across 7 European Registries
A multinational registry analysis of RA receiving abatacept (ABA) has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy.
https://t.co/CVeAV0ZXA8 https://t.co/A8McLt0rSl
Links:
Dr. John Cush RheumNow ( View Tweet)
2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis
These included 5 overarching principles & 10 recos on the role of imaging in making a diagnosis, monitoring, predicting, guiding therapy, and patient education in CiA.
https://t.co/OaRBNfhNCJ https://t.co/gF9QFDYTsu
Links:
Dr. John Cush RheumNow ( View Tweet)
Uncertainty can be worrisome. When uncertainty lies ahead, optimism and preparation are your best navigators. Im an optimist. https://t.co/JNzWJFMEfV https://t.co/ltIdy6hNqn
Links:
Dr. John Cush RheumNow ( View Tweet)
Medicare and Commercial claims analysis shows
1 #RA pts at risk for H Zoster
2 RA + HZ = more Hospitalizations & ED visits, esp in 30d after HZ
3 Higher total costsalso higher in month after HZ
https://t.co/gFlsLDIxVB https://t.co/733W3Kv3WC
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 28,360 #PsA pts shows blacks have signif more HTN (59 v 52%), DM (31 v 23%), obesity (47 v 30%), gout (12 v 8%); while whites have more cancer (20 v 16%), anxiety (28 v 23%) & OP (14 v 12). Rx (NSAIDs, TNFi, DMARDs) also unequal by race. https://t.co/Ok7vhTdS8g https://t.co/ozFIg9HNuy
Links:
Dr. John Cush RheumNow ( View Tweet)
Arborviral infx w/ rituximab? 21 RTX pts dx w/ arboviral neuroinvasive Dz, (encephalitis, acute flaccid myelitis); 79% died. B cell depletion impairs immunity & spread of West Nile Virus, serologic Ab Dx tests; thus if suspected, order RT-PCR tests https://t.co/yQiXI2IYqd https://t.co/dZX2CQJs0L
Links:
Dr. John Cush RheumNow ( View Tweet)
Small study 57 EGPA pts shows using MTX or AZA to be equipotent as 1st or 2nd line therapy in EGPA. MTX pts used more cumulative steroids (6 g vs 10.7 g @5 yrs) & more AE (66% vs 30%); AZA had fewer asthma/ENT relapses (23% vs 64%, p= 0.04) https://t.co/WZHudojrzk https://t.co/X6xITcQtCw
Links:
Dr. John Cush RheumNow ( View Tweet)
Predictors of DAPSA28 remission in #PsA starting 1st TNF-inhibitor (13 369 bio-naive pts from 13 Euro registries) showed 6 mo remission 25% and 12 retention 63%. Remission predictors: younger age, Dz duration, males (OR 1.85), CRP >10 (OR 1.52) https://t.co/cTefy6xeUB https://t.co/b2Ok6HJgE1
Links:
Dr. John Cush RheumNow ( View Tweet)
HRT for RA? Not Yet
Dr. Aurelie Najm discusses OP0268 presented at EULAR 2023 in Milan, Italy.
@AurelieRheumo
https://t.co/hoyZ2Ezn4G https://t.co/XWfE1RHwpi
Links:
Dr. John Cush RheumNow ( View Tweet)
Abatacept Safety Outcomes Across 7 European Registries
A multinational registry analysis of rheumatoid arthritis receiving abatacept has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy.
https://t.co/XcOSLTgQVR https://t.co/ZfwAA0baRM
Links:
Dr. John Cush RheumNow ( View Tweet)